Stock A235980 MEDPACTO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials MedPacto, Inc.

Equities

A235980

KR7235980000

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 04/07/2024 BST 		5-day change 1st Jan Change
7,990 KRW +6.53% Intraday chart for MedPacto, Inc. +12.54% +10.36%
2023 MedPacto, Inc. announced that it has received KRW 10.85806127 billion in funding from Theragen Etex Co.,Ltd. CI
2023 South Korean Shares Nearly Unchanged Ahead of US Inflation Data MT

Valuation

Fiscal Period: December 2020 2021 2022 2023
Capitalization 1 2,393,411 1,201,906 469,045 243,124
Enterprise Value (EV) 1 2,348,548 1,080,523 435,468 172,948
P/E ratio -94.2 x -70.4 x -13 x -4.35 x
Yield - - - -
Capitalization / Revenue - - - -
EV / Revenue - - - -
EV / EBITDA -89.1 x -39 x -12.3 x -6.42 x
EV / FCF - -46,082,764 x -20,444,115 x -8,486,721 x
FCF Yield - -0% -0% -0%
Price to Book 43 x 27.6 x 14.5 x 3.43 x
Nbr of stocks (in thousands) 20,335 20,510 21,081 33,581
Reference price 2 117,700 58,600 22,250 7,240
Announcement Date 14/03/22 14/03/22 13/03/23 20/03/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023
Net sales - - - -
EBITDA 1 -26,363 -27,736 -35,380 -26,919
EBIT 1 -27,800 -29,459 -37,246 -28,752
Operating Margin - - - -
Earnings before Tax (EBT) 1 -25,352 -17,040 -35,753 -35,325
Net income 1 -25,352 -17,040 -35,753 -35,325
Net margin - - - -
EPS 2 -1,249 -832.3 -1,705 -1,665
Free Cash Flow - -23,447 -21,300 -20,379
FCF margin - - - -
FCF Conversion (EBITDA) - - - -
FCF Conversion (Net income) - - - -
Dividend per Share - - - -
Announcement Date 14/03/22 14/03/22 13/03/23 20/03/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023
Net Debt 1 - - - -
Net Cash position 1 44,863 121,383 33,577 70,177
Leverage (Debt/EBITDA) - - - -
Free Cash Flow - -23,447 -21,300 -20,379
ROE (net income / shareholders' equity) - -34.3% -87.2% -61.1%
ROA (Net income/ Total Assets) - -19.2% -19.3% -19.1%
Assets 1 - 88,772 185,099 184,941
Book Value Per Share 2 2,740 2,122 1,533 2,112
Cash Flow per Share 2 132.0 63.00 17.10 2,162
Capex 1 718 757 878 101
Capex / Sales - - - -
Announcement Date 14/03/22 14/03/22 13/03/23 20/03/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
MEDPACTO, INC. Stock MedPacto, Inc.
+10.36% 194M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+16.61% 122B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+17.75% 112B
ARGENX SE Stock argenx SE
+17.73% 25.91B
BIONTECH SE Stock BioNTech SE
-24.11% 19.33B
GENMAB A/S Stock Genmab A/S
-18.56% 16.17B
BEIGENE, LTD. Stock BeiGene, Ltd.
-18.47% 15.6B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-47.75% 14.65B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+57.35% 14.34B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.62% 14B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. A235980 Stock
  4. Financials MedPacto, Inc.